MedPath

Itolizumab

Generic Name
Itolizumab
Drug Type
Biotech
CAS Number
1116433-11-4
Unique Ingredient Identifier
XQQ2RHV14N

Overview

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Background

Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath